HB0017 clinical trials
Also written HB0017.
How each study uses HB0017 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HB0017
- 3
Studies by the year they started
4 studies that test it; most in 2024 (2)
| Year | Studies |
|---|---|
| 2020 | 1 |
| 2022 | 1 |
| 2024 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Huabo Biopharm Co., Ltd. (4)
Studies
Open first, then newest update. How each study uses HB0017 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- A Phase 2 Study of HB0017 in Psoriasis PatientsCompletedPhase 2Huabo Biopharm Co., Ltd.NCT06592274Written as HB0017
- Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 3Huabo Biopharm Co., Ltd.NCT06477237Written as HB0017 Q4W
- A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisCompletedPhase 2Huabo Biopharm Co., Ltd.NCT05531682Written as HB0017
- A Study of Injection HB0017 in Adult Healthy VolunteersCompletedPhase 1Huabo Biopharm Co., Ltd.NCT04505033Written as HB0017